United States Patent 5,494,799: Claim-by-Claim Analysis and U.S. Patent Landscape for Gamma-Interferon Whole-Blood Antigen Diagnostic Kits

US Patent 5,494,799 claims diagnostic kits that measure gamma interferon (IFN-γ) released by sensitized lymphocytes in whole blood after incubation with a specific antigen, using immunoassay formats such as ELISA or RIA. The claims anchor on (1) whole-blood incubation with antigen, (2) detection of IFN-γ as the readout for cell-mediated immunity, and (3) antigen scope including tuberculosis complex members and, in cattle, M. bovis PPD.

This analysis focuses on what is actually claimed, where the claims are vulnerable, and how the surrounding U.S. landscape likely treats these feature combinations.

What do the claims actually cover (and what do they not)?

Core claim construct (Claim 1 as the base)

Claim 1 defines a “diagnostic kit” with three functional elements:

Source of the specific antigen
Means for incubating the specific antigen with whole blood (human or animal)
Means for detecting IFN-γ released by sensitized lymphocytes in the whole blood to indicate a cell-mediated immune response to that antigen

The claim does not require:

any specific antigen preparation other than “a source of the specific antigen”
any particular incubation time, temperature, ratio, or incubation medium beyond “whole blood”
any particular device geometry (tube formats, plate types) or workflow steps beyond incubation and detection
any specific lymphocyte stimulation technology beyond using the antigen to elicit IFN-γ in sensitized lymphocytes
any confirmatory criteria (cutoffs, controls) within the claim text provided

The claim also covers both human and animal diagnostics, and it is drafted to be broad on assay readout method (the detection “means” is functional, then narrowed in dependent claims).

Dependent claim narrowing (Claims 2 and 3)

Claim 2 narrows the “detecting IFN-γ” means to an immunoassay for IFN-γ.
Claim 3 narrows further to ELISA or RIA as assay formats.

Thus, the legal scope tightens around commercializable assay classes rather than novel biological steps.

Antigen-specific scope (Claims 4, 6, 7, 5, 9)

Claims 4 and 6 cover antigen classes from:
- Mycobacterium bovis, Mycobacterium paratuberculosis, or Mycobacterium tuberculosis
Claim 7 states the immunoassay version with those antigen classes.
Claim 5 and Claim 9 are cattle-directed, specifying M. bovis antigen, tuberculin purified protein derivative (PPD).

The cattle versions are likely the most commercially salient because M. bovis and PPD are the most standard regulatory targets in bovine tuberculosis testing programs.

Where are the strongest claim elements from an enforceability perspective?

1) Whole-blood incubation with antigen as a required step

Claim 1 requires incubation of antigen with whole blood and subsequent measurement of IFN-γ released by sensitized lymphocytes. This is a meaningful technical limitation because it excludes workflows that use separated peripheral blood mononuclear cells (PBMCs) as the stimulation substrate, if those workflows are not “whole blood.”

A design-around could still exist if:

the platform uses a blood fraction not legally “whole blood,” or
it uses a stimulation substrate that includes blood but is not whole blood in a strict sense.

But the claim language is tight enough that whole blood versus PBMC platforms are not interchangeable in a typical infringement analysis.

2) IFN-γ release is the immune-response indicator

Claim 1 ties the detection readout to IFN-γ released by sensitized lymphocytes. That is narrower than generic “cytokine detection” or “T-cell response” without specifying IFN-γ.

Assay readouts that target IL-2, TNF-α, or other cytokines without IFN-γ as the primary release metric would not map cleanly to this claim.

3) ELISA/RIA are explicit in dependent claims

Dependent claims 2 and 3 narrow to immunoassay detection, then to ELISA or RIA. If competitors use multiplex bead assays, electrochemiluminescence, lateral flow, or ELISA variants, mapping depends on whether those fall within “ELISA” as claimed and whether the claim construction interprets “immunoassay means comprises” broadly.

For enforcement, the dependent claims can still be valuable:

they provide a hook for “traditional” ELISA/RIA formats,
while the independent claim potentially covers other immunoassays under the functional “means” language (but only for IFN-γ detection after whole-blood incubation with antigen).

Where are the claims vulnerable to prior art and invalidity?

1) The claim reads like a method-technology combination with broad functional “means”

The claims are drafted as a kit with “means for incubating” and “means for detecting” IFN-γ. In many older diagnostics and immunology patents, such “means” language risks being treated as covering known implementations rather than requiring a new mechanism.

If prior art already disclosed:

stimulating whole blood with a mycobacterial antigen,
measuring IFN-γ release,
using immunoassay detection formats such as ELISA,

then the novelty may be thin at the kit level.

The dependent claim structure narrows but does not add procedural constraints (incubation duration, controls, calibration, or gating rules). That increases invalidity risk if the overall concept was known.

2) Antigen identity is specified, but the general immune-detection architecture is not novel

Claims 4/6/7 specify antigen sources for tuberculosis complex and MAP (M. paratuberculosis). However, the architecture is antigen-agnostic except for “specific antigen,” then later enumerated.

If prior art taught IFN-γ release diagnostics for tuberculosis using antigen stimulation, those disclosures can potentially anticipate the broader kit logic even if the particular antigen subset differs.

For example:

If prior art used PPD or ESAT-6-like antigens, the antigen substitution question becomes central.
Claim 1 would still be broad enough to cover those kits if “specific antigen” is supplied and whole blood is used with IFN-γ readout.

3) ELISA/RIA for IFN-γ is historically well known

ELISA and RIA are classic IFN-γ detection formats. If prior art already used those assay modalities to quantify released IFN-γ from antigen-stimulated blood, then dependent claims 2 and 3 can be anticipated even if the kit as a whole differed in minor packaging.

The enforceability question becomes: does the prior art combine those known assays with the required whole blood + antigen + IFN-γ release steps?

4) The cattle PPD claims are likely close to regulatory-era prior art

Claim 5 and Claim 9 tie to M. bovis PPD in cattle. If earlier patents and publications already described IFN-γ release assays for bovine TB using PPD as the antigen in whole blood, these are prime targets for invalidity arguments.

How does this patent fit into the U.S. landscape for IFN-γ tuberculosis diagnostics?

Landscape pattern: “IFN-γ release assay” families

The claim set matches a known technical paradigm: stimulate blood with mycobacterial antigen, measure released IFN-γ. In the U.S. patent landscape, this paradigm tends to appear in clusters where each family:

fixes the antigen(s) used,
fixes the blood source and processing (whole blood vs PBMC),
fixes the assay readout and format (ELISA, RIA, or other),
and sometimes fixes controls and interpretation logic.

US 5,494,799 is built around the most generic core of that paradigm:

whole blood
IFN-γ
antigen stimulation
immunoassay detection, including ELISA/RIA in dependent claims

As a result, the patent is positioned as a broad kit claim that can be attacked by any prior art family that already teaches the same core combination, even if the antigen details differ.

Breadth vs. differentiators

Compared with later, more specific TB diagnostic patents, this one is light on differentiators:

No requirement for specific antigen epitopes (like ESAT-6/CFP-10) in the provided claim set
No explicit requirement for control conditions (e.g., mitogen positive control) in the provided text
No explicit requirement for cutoffs, calculation methods, or interpretive algorithms

So if the market moved toward antigen panels and more complex interpretation rules, those later patents could claim novelty in those differentiators rather than the foundational whole-blood IFN-γ measurement concept.

Which design-arounds are most likely to avoid infringement?

1) Avoid “whole blood” as the stimulation substrate

Competitors can switch to PBMC-based stimulation. If “whole blood” is construed strictly, PBMC workflows should weaken infringement mapping for Claim 1’s “means for incubating said specific antigen with a whole blood sample.”

2) Avoid IFN-γ as the measured cytokine readout

Switching to cytokines other than IFN-γ could remove an essential element of all claims that require detection of gamma interferon released by sensitized lymphocytes.

3) Avoid ELISA/RIA in dependent claim scope

If a competitor uses a different IFN-γ immunoassay format (not ELISA or RIA), dependent Claims 2-3 may be easier to avoid, while Claim 1 could still be asserted depending on the construction of “immunoassay” in Claim 2 and the breadth of “means for detecting.”

4) Change assay architecture away from “released by sensitized lymphocytes in the whole blood sample”

The claim text ties IFN-γ to sensitized lymphocytes and whole blood incubation. If a system measures IFN-γ in a different context, or uses ex vivo cell systems that are not “in the whole blood sample,” infringement may be harder to establish.

What is the likely strongest infringement profile for this patent?

This patent is most enforceable where products match all required elements of Claim 1 and, ideally, the ELISA/RIA formats of Claims 2-3.

A product maps well if it:

provides an antigen source (e.g., PPD or related TB antigen)
stimulates antigen with whole blood
measures IFN-γ release in the stimulated whole blood sample
uses an immunoassay for IFN-γ (with ELISA/RIA being the cleanest match)

Cattle-specific products using M. bovis PPD with whole-blood IFN-γ readout are particularly aligned to Claims 5 and 9.

Critical assessment of claim coverage quality (commercial and legal)

Commercially

The kit concept is commercially plausible and technology-aligned to common “lab-in-a-box” cytokine testing products.
The inclusion of tuberculosis and related mycobacteria plus cattle PPD scope makes the claims directly relevant to two of the largest veterinary immunodiagnostic markets.

Legally

The independent claim is broad and functional. That increases claim reach but decreases novelty.
Dependent claims provide narrower assay format hooks (ELISA/RIA) but those assay modalities were historically common.
Without specific antigen epitopes, incubation parameters, or interpretive logic, the claims risk being anticipated by earlier “IFN-γ release assay” disclosures that already combine the essential core.

Net effect: enforcement will likely depend on whether a prior art gap exists at the time of filing, especially around the required combination of:

whole blood incubation + mycobacterial antigen stimulation + IFN-γ measurement by immunoassay.

Key claim mapping table

Claim	Required elements (from provided text)	Practical mapping target
1	Kit; antigen source; incubate antigen with whole blood (human/animal); detect IFN-γ released by sensitized lymphocytes	Broad IFN-γ release whole-blood kits for antigen-stimulated immune readout
2	Claim 1 + immunoassay for IFN-γ	Products using any IFN-γ immunoassay format (ELISA/RIA still fall here)
3	Claim 2 + ELISA or RIA for IFN-γ	Classic plate-based ELISA or radioassay readouts
4	Claim 1 + antigen is M. bovis, M. paratuberculosis, or M. tuberculosis	TB/MAP antigen-stimulated IFN-γ diagnostics
5	Claim 1 + cattle; antigen is M. bovis antigen or PPD	Bovine TB IFN-γ whole-blood PPD tests
6	Claim 1 + antigen is M. bovis, M. paratuberculosis, or M. tuberculosis	Redundant coverage variant; depends on claim drafting consistency
7	Claim 3 + antigen is M. bovis, M. paratuberculosis, or M. tuberculosis	ELISA/RIA IFN-γ immunoassays using those antigens
8	Independent kit language variant: antigen group (M. bovis, M. paratuberculosis, M. tuberculosis), whole blood incubation, IFN-γ detection	Broader “group” antigen kit restatement
9	Independent kit language variant for cattle: M. bovis antigen/PPD; whole blood incubation; IFN-γ detection	Direct cattle PPD whole-blood kits

Key Takeaways

US 5,494,799 claims whole-blood antigen stimulation and IFN-γ release measurement as the diagnostic core, with immunoassay detection and ELISA/RIA narrowing in dependent claims.
The antigen scope includes tuberculosis complex members and MAP (M. paratuberculosis), with dedicated cattle claims for M. bovis antigen and PPD.
Enforceability is strongest against products that replicate the full combination: whole blood + mycobacterial antigen + IFN-γ immunoassay readout (especially ELISA/RIA).
The claims are vulnerable if prior art already disclosed the same core combination because the provided claim set lacks deeper technical differentiators (epitope choice, incubation conditions, control logic, or specific assay interpretation rules).

FAQs

1) What is the single most important element of US 5,494,799?
The patent’s core requirement is measuring IFN-γ released by sensitized lymphocytes after incubating a specific antigen with whole blood.

2) Which claims explicitly mention ELISA or RIA?
Claim 3.

3) Are the claims limited to tuberculosis only?
No. They include Mycobacterium paratuberculosis (MAP) and Mycobacterium bovis and Mycobacterium tuberculosis, based on the antigen scope in Claims 4, 6, 7, and 8.

4) Do the cattle claims focus on PPD?
Yes. Claims 5 and 9 specify tuberculin PPD alongside M. bovis antigen for cattle.

5) What is the most likely way competitors avoid the claims?
Avoid at least one essential element: use PBMC instead of whole blood, measure a cytokine other than IFN-γ, or avoid the specific ELISA/RIA formats in the dependent claim scope.

References

[1] United States Patent 5,494,799. “Diagnostic kit for detection of cell-mediated immune response to specific antigen using gamma interferon.” (Claims provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Par Pharmaceutical Companies, Inc.	APLISOL	tuberculin, purified protein derivative	Injection	103782	April 20, 1998	5,494,799	2014-04-20
Sanofi Pasteur Limited	TUBERSOL	tuberculin, purified protein derivative	Injection	103941	February 24, 2000	5,494,799	2014-04-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 5,494,799

Summary for Patent: 5,494,799